Decisions Made Today Shape Commercial Success Tomorrow

Biopharma executives often treat operational readiness and commercialization planning as separate disciplines, deferring readiness until a product nears commercialization. When packaging configurations, logistic strategies, manufacturing approaches, or distribution networks are not evaluated early, organizations may discover late in development that a critical component of their commercial strategy is not viable at scale. The consequences can lead to repeated studies and delays. In conversation with Pharmaceutical Commerce, Gwen Erskine, Senior Director of Consulting Services at Cryoport Systems, explains why readiness begins at the start when considering how a product will be manufactured, distributed, and delivered to patients. She outlines what questions leadership teams should be asking and the signs companies should look for that will unknowingly create future challenges. Executives will gain insight into early-stage decisions that will not only position their organization for growth, but strengthen partnerships to support a full product lifecycle.

Learning Objectives:

1. Explain why commercialization readiness begins much sooner than executives think.
2. Identify early operational decisions—product handling requirements, product configuration, transportation strategies, temperature management requirements, and supply chain design—that affect commercial scalability and launch readiness.
3. Describe how cross-functional alignment among development, regulatory, quality, operations, and commercial teams can reduce late-stage risk and the cost of correcting mistakes.

DOWNLOAD